SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/21 Biolase, Inc. 10-K 12/31/20 88:15M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 1.28M 2: EX-4.13 Instrument Defining the Rights of Security Holders HTML 52K 3: EX-10.41 Material Contract HTML 52K 4: EX-10.44 Material Contract HTML 55K 5: EX-21.1 Subsidiaries List HTML 23K 6: EX-23.1 Consent of Expert or Counsel HTML 24K 7: EX-31.1 Certification -- §302 - SOA'02 HTML 31K 8: EX-32.1 Certification -- §906 - SOA'02 HTML 26K 15: R1 Document and Entity Information HTML 90K 16: R2 Consolidated Balance Sheets HTML 119K 17: R3 Consolidated Balance Sheets (Parenthetical) HTML 56K 18: R4 Consolidated Statements Of Operations And HTML 121K Comprehensive Loss 19: R5 Consolidated Statements Of Redeemable Preferred HTML 134K Stock And Shareholders' Equity 20: R6 Consolidated Statements Of Redeemable Preferred HTML 31K Stock And Shareholders' Equity (Parenthetical) 21: R7 Consolidated Statements Of Cash Flows HTML 164K 22: R8 Basis of Presentation HTML 39K 23: R9 Summary of Significant Accounting Policies HTML 260K 24: R10 Supplementary Balance Sheet Information HTML 150K 25: R11 Intangible Assets and Goodwill HTML 65K 26: R12 Income Taxes HTML 246K 27: R13 Debt HTML 120K 28: R14 Commitments and Contingencies HTML 108K 29: R15 Redeemable Preferred Stock and Stockholders' HTML 376K Equity 30: R16 Segment Information HTML 52K 31: R17 Concentrations HTML 88K 32: R18 Subsequent Events HTML 29K 33: R19 Schedule II-Consolidated Valuation and Qualifying HTML 117K Accounts and Reserves 34: R20 Summary of Significant Accounting Policies HTML 329K (Policies) 35: R21 Summary of Significant Accounting Policies HTML 241K (Tables) 36: R22 Supplementary Balance Sheet Information (Tables) HTML 137K 37: R23 Intangible Assets and Goodwill (Tables) HTML 63K 38: R24 Income Taxes (Tables) HTML 247K 39: R25 Debt (Tables) HTML 60K 40: R26 Commitments and Contingencies (Tables) HTML 98K 41: R27 Redeemable Preferred Stock and Stockholders' HTML 350K Equity (Tables) 42: R28 Segment Information (Tables) HTML 47K 43: R29 Concentrations (Tables) HTML 87K 44: R30 Basis of Presentation - Additional Information HTML 49K (Detail) 45: R31 Summary of Significant Accounting Policies - HTML 136K Additional Information (Detail) 46: R32 Schedule of Reconciliation of Cash, Cash HTML 34K Equivalents, and Restricted Cash (Detail) 47: R33 Estimated Useful Lives of Property, Plant and HTML 38K Equipment (Detail) 48: R34 Summary of Opening and Closing Balances of HTML 36K Contract Liabilities (Detail) 49: R35 Summary of Disaggregation of Revenues Related to HTML 34K Geographic Areas (Detail) 50: R36 Summary of Revenues Disaggregated by Timing of HTML 34K Goods and Services Transferred (Detail) 51: R37 Summary of Sales by End Market (Detail) HTML 34K 52: R38 Changes in Initial Product Warranty Accrual and HTML 38K Expenses Under Initial and Extended Warranties (Detail) 53: R39 Classification of Compensation Expense Associated HTML 37K with Share-Based Payments (Detail) 54: R40 Assumptions Used in Estimating Fair Value of Stock HTML 32K Options Granted (Detail) 55: R41 Components of Accounts Receivable, Net of HTML 29K Allowance (Detail) 56: R42 Supplementary Balance Sheet Information - HTML 44K Additional Information (Detail) 57: R43 Components of Inventory (Detail) HTML 33K 58: R44 Components of Prepaid Expenses and Other Current HTML 33K Assets (Detail) 59: R45 Summary of Property, Plant, and Equipment (Detail) HTML 48K 60: R46 Components of Accrued Liabilities (Detail) HTML 44K 61: R47 Intangible Assets and Goodwill - Additional HTML 31K Information (Detail) 62: R48 Intangible Assets and Related Accumulated HTML 51K Amortization (Detail) 63: R49 Summary of Income Tax Current and Deferred HTML 45K Provision (Detail) 64: R50 Federal Income Tax Provision Compared With HTML 49K Statutory Rates (Detail) 65: R51 Summary of Net Deferred Tax Assets and Net HTML 69K Deferred Tax Liabilities (Detail) 66: R52 Income Taxes - Additional Information (Detail) HTML 44K 67: R53 Summary of Unrecognized Tax Benefits (Detail) HTML 31K 68: R54 Debt - Summary of Principal Outstanding and HTML 40K Unamortized Discount (Detail) 69: R55 Debt - Additional Information (Detail) HTML 440K 70: R56 Debt - Summary of Future Minimum Principal HTML 48K Payments (Detail) 71: R57 Commitments and Contingencies - Additional HTML 111K Information (Detail) 72: R58 Commitments and Contingencies - Information HTML 34K related to Right-of-use Assets and Liabilities (Detail) 73: R59 Future Minimum Rental Commitments Under Lease HTML 46K Agreements (Detail) 74: R60 Redeemable Preferred Stock and Stockholders' HTML 382K Equity - Additional Information (Detail) 75: R61 Summary of Warrant Activity (Detail) HTML 57K 76: R62 Summary of Option Activity (Detail) HTML 67K 77: R63 Options Outstanding and Exercisable (Detail) HTML 63K 78: R64 Cash Proceeds Along with Fair Value Disclosures HTML 32K Related to Grants, Exercises, and Vesting Options (Detail) 79: R65 Summary of Unvested Restricted Stock Units HTML 36K (Detail) 80: R66 Segment Information - Additional Information HTML 37K (Detail) 81: R67 Summary of Long-Lived Assets by Geographic HTML 32K Location (Detail) 82: R68 Concentrations - Summary of Net Revenue from HTML 51K Various Products (Detail) 83: R69 Concentrations - Additional Information (Detail) HTML 33K 84: R70 Subsequent Events - Additional Information HTML 57K (Detail) 85: R71 Consolidated Valuation and Qualifying Accounts and HTML 40K Reserves (Detail) 87: XML IDEA XML File -- Filing Summary XML 157K 86: EXCEL IDEA Workbook of Financial Reports XLSX 135K 9: EX-101.INS XBRL Instance -- biol-20201231 XML 4.27M 11: EX-101.CAL XBRL Calculations -- biol-20201231_cal XML 268K 12: EX-101.DEF XBRL Definitions -- biol-20201231_def XML 859K 13: EX-101.LAB XBRL Labels -- biol-20201231_lab XML 2.02M 14: EX-101.PRE XBRL Presentations -- biol-20201231_pre XML 1.48M 10: EX-101.SCH XBRL Schema -- biol-20201231 XSD 280K 88: ZIP XBRL Zipped Folder -- 0001564590-21-017121-xbrl Zip 271K
Exhibit10.44
SEPARATION AGREEMENT WITH GENERAL RELEASE OF ALL CLAIMS
This Separation Agreement With General Release of All Claims (“Agreement”) is entered into by and between Todd Norbe (“Mr. Norbe”), and Biolase, Inc., a Delaware corporation (the “Company”), and is intended by the parties hereto to settle fully and finally any claims that Mr. Norbe may have against the Company and all obligations of the Company to Mr. Norbe, except as set forth in and incorporated into this Agreement.
a. |
Employment Separation. Mr. Norbe’s employment with the Company ended effective February 22, 2021 (the “Separation Date”). From and after the Separation Date, Mr. Norbe shall no longer be employed by, or act in any capacity (including as a director) for, the Company, and Mr. Norbe hereby resigns as a Director of the Company, and from all Company positions held and on any Company subsidiary boards as of the Separation Date. |
b. |
Termination Pay. Mr. Norbe acknowledges that he has been paid his base salary and accrued but unused vacation through the Separation Date (“Termination Pay”). Mr. Norbe shall submit expense reimbursement requests with suitable documentation within thirty (30) days following the Separation Date, and the Company shall promptly process such requests in accordance with its expense reimbursement policies. |
c. |
Severance Payment; COBRA Premiums. In consideration for the promises contained herein and subject to Mr. Norbe’s continued compliance with the terms and conditions of this Agreement and his execution and non-revocation of this Agreement within the timeframe specified herein, Mr. Norbe shall receive the following benefits: |
|
i. |
$412,000.00, payable in twenty-six (26) equal installments, beginning on the first regular payroll date following the sixty (60) day anniversary from the Separation Date, coinciding with the Company’s regular payroll cycle; and |
|
ii. |
Subject to Mr. Norbe’s timely election of COBRA continuation coverage, Company-paid COBRA premiums for Mr. Norbe (and his eligible dependents) under the Company’s medical and dental benefit plans in which Mr. Norbe participated in as of the Separation Date, for the twelve (12) month period following the Separation Date. |
d. |
Vested Retirement Benefits. Nothing in this Agreement shall limit, expand upon, or alter in any way any vested retirement benefits that Mr. Norbe has or is entitled to receive under any Company sponsored 401(k) or other retirement plan to which Mr. Norbe may have been entitled to participate by virtue of his employment. Mr. Norbe’s rights and obligations shall continue to be governed by the terms of such plans, as they presently exist or as they may permissibly be amended, and shall be based upon his Separation Date. |
e. |
No Other Payments. Other than whatever is specifically provided for in this Agreement, Mr. Norbe acknowledges that there are no other sums or benefits of any nature whatsoever due and owing to him, including without limitation any sums or benefits set forth in that certain Employment Agreement, dated August 7, 2018, by and between the Company and Mr. Norbe, as amended (the “Employment Agreement”), other than whatever payments or benefits are specifically provided for and set forth in this Agreement. In consideration for this Agreement, Mr. Norbe specifically waives any claim that he may have to any past, present, or future compensation of any nature whatsoever arising out of his prior employment with the Company. |
f. |
Confirmation Of Payment Of Wages. Mr. Norbe acknowledges that he has been paid all wages due and owing to him from the Company, including all minimum wages, overtime compensation, commissions, bonuses, waiting-time penalties, and liquidated damages. Accordingly, Mr. Norbe understands that the release provisions below release and discharge the Company from any and all claims that he may have against the Company for unpaid wages and other compensation including, but not limited to, any claims for unpaid wages, salary, bonuses, commissions, stock, stock options, vacation pay, holiday pay, sick or disability pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation. |
g. |
Biolase Proprietary Information. As a material inducement to Biolase to enter into this Agreement, Mr. Norbe covenants and represents that (i) he has complied with the terms and conditions of the Biolase Proprietary Information Agreement at all times during his employment with Biolase; and (ii) he will continue to comply with such terms for the periods specified therein. The terms of the Biolase Proprietary Agreement are incorporated into this Agreement by reference and made a part hereof. |
h. |
Continuing Obligations of Mr. Norbe. To the extent that Mr. Norbe has come into contact with confidential or trade secret information concerning the Company and its operations or concerning the Company’s customers, prospective customers, or projects, Mr. Norbe will continue to protect the confidentiality of such information. In addition, Mr. Norbe represents and warrants that, except with respect to those items communicated by the Company to Mr. Norbe in writing (electronic mail acceptable), he has returned to the Company and has not copied or duplicated in any manner whatsoever, all tangible and intangible property (including, without limitation, all computer hardware, whether portable or stationary, and software), books, records, documents and reports owned by, or pertaining to the business of, the Company or any of the Company’s existing or prospective clients that was in Mr. Norbe’s possession or under Mr. Norbe’s direct or indirect control as of the Separation Date. If Mr. Norbe shall come into possession of any property (tangible or intangible), books, records, documents or reports of the type described above after the Separation Date, Mr. Norbe will promptly return them to the Company. |
i. |
Complete Release. Mr. Norbe, on behalf of himself, his heirs and assigns, fully and forever releases and discharges the Company and, as the case may be, each of its respective employees, shareholders, officers, directors, agents, attorneys, predecessors, successors, assigns, and affiliated corporations or organizations, whether previously or hereafter affiliated in any manner (collectively, the “Released Company Parties”), to the fullest extent permitted by law, from any and all claims, demands, causes of action, charges of discrimination, obligations, damages, attorneys’ fees, costs and liabilities of any nature whatsoever, including all claims of race, sex, national origin, religion, handicap and age discrimination under any federal or state statute, whether or not now known, suspected or claimed of any nature, including without limitation any claims, demands, causes of action, charges of discrimination, obligations, damages, attorneys’ fees, costs and liabilities of any nature in connection with the Employment Agreement, which Mr. Norbe ever had, now has, or may claim to have as of the date of this Agreement against the Released Company Parties. |
2
may be adjudicated before the California Workers’ Compensation Appeals Board, claims for vested benefits or any claims for enforcement of any other provision of this Agreement. This Release specifically includes, without limiting the generality of the foregoing, any claims against any Released Company Party occurring before the date of this Agreement and arising out of or related to alleged violations of any federal or state employment discrimination laws, including, but not limited to, the California Fair Employment and Housing Act; the Age Discrimination In Employment Act; the Older Workers Benefit Protection Act; Title VII of the Civil Rights Act of 1964; the Americans With Disabilities Act; the National Labor Relations Act; the Equal Pay Act; the Employee Retirement Income Security Act of 1974; as well as claims arising out of or related to violations of the provisions of the California Government Code; the California Business & Professions Code, including Business & Professions Code Section 17200 et seq.; state and federal wage and hour laws; breach of contract; fraud; misrepresentation; common counts; unfair competition; unfair business practices; negligence; defamation; infliction of emotional distress; invasion of privacy; assault; battery; false imprisonment; wrongful termination; and any other state or federal law, rule, or regulation. Mr. Norbe acknowledges that his separation and the consideration offered hereunder were based on an individual determination and were not offered in conjunction with any group termination or group severance program and waives any claim to the contrary, and further acknowledges that he does not presently believe he has suffered any work-related injury or illness. |
k. |
Release of Unknown Claims. It is the intention of Mr. Norbe to release both known and unknown claims of any nature whatsoever. This includes, without limitation, claims, which Mr. Norbe does not know or suspect to exist in his favor at the time of executing this release, even though such claims, if known by him would have materially affected his settlement with the Company. Accordingly, Mr. Norbe expressly waives all rights under Section 1542 of the Civil Code of the State of California, which reads as follows: |
“A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor.”
l. |
Non-Disparagement; Non-Solicitation; Neutral Reference. Mr. Norbe agrees during the term of this Agreement and for a period of ten (10) years thereafter, he shall not, in any communication with any person or entity, including any actual or potential customer, client, investor, vendor, or business partner of the Company, or any third party media outlet, make any derogatory or disparaging or critical negative statements – orally, written or otherwise – against the Company, or any of its directors, officers, agents, employees, contractors, or affiliated persons or entities. Mr. Norbe also agrees that unless compelled by valid legal process he will not give or offer to provide any statements, testimony or the like in connection with any claim, action, or demand (being contemplated or) brought against the Company which concerns the Company, his employment or the cessation of his employment with the Company, the Company’s business practices, its customers and/or prospective customers, its products, and/or any other aspect of the Company’s business, its directors, officers, agents, employees, contractors, or affiliated persons or entities. Further, Mr. Norbe agrees that if he agrees that should he be called as a witness or to provide testimony in any case, action, and/or proceeding concerning the Company, he and/or his counsel will contact either the Chief Executive Officer or the Secretary / General Counsel of the Company immediately, but in no event later than ten (10) days before he is to be deposed or to testify as a witness, so that the Company can take whatever precautionary measures it deems necessary to protect from disclosure any of its proprietary and/or confidential information and/or documents. Executive agrees that during the twenty-four |
3
(24) month period following the Separation Date he shall not, directly or indirectly, through any other individual or entity, solicit any employee of the Company, to cease his or her employment with the Company, and Mr. Norbe will not approach any such employee for any such purpose or knowingly authorize the taking of any such action by any other individual or entity. Mr. Norbe further agrees that for the twenty-four (24) period following the Separation Date, Mr. Norbe shall not, without the prior written approval of the Company, directly or, with knowledge, indirectly, through or on behalf or any other individual or entity, solicit, entice or induce any business from any of the Company’s customers (including actively sought prospective customers) or suppliers/vendors, the identity of whom, or information concerning, rises to the level of a “trade secret” within the meaning of the Uniform Trade Secrets Act (“UTSA”). |
m. |
No Other Actions. Mr. Norbe represents and covenants that he has not filed or lodged any complaints or charges against any of the Released Company Parties with any local, state, or federal agency or court. |
n. |
Risk of Different Facts. The parties to this Agreement acknowledge that they may hereafter discover facts different from or in addition to those they now know or believe to be true, and they expressly agree to assume the risk of the possible discovery of additional or different facts, and agree that this Agreement shall be and remain effective in all respects regardless of such additional or different facts. |
o. |
No Future Actions. Mr. Norbe covenants and agrees never to commence, aid in any way, prosecute or cause to be commenced or prosecuted any action or other proceeding based upon any claims, demands, causes of action, obligations, damages or liabilities which are the subject of this Agreement; provided however, that Mr. Norbe does not relinquish any protected rights he may have to file a charge, testify, assist or participate in any manner in an investigation, hearing or proceeding conducted by the Equal Employment Opportunity Commission, the Office of Federal Contract Compliance, or any similar state human rights agency. However, Mr. Norbe may not recover additional compensation or damages as a result of such participation. |
p. |
Twenty-One Day Consideration Period. This Agreement was originally given to Mr. Norbe on the Separation Date. Mr. Norbe shall have twenty-one (21) days to consider this Agreement; provided however, that if Mr. Norbe chooses to sign this Agreement before the end of this twenty-one (21)-day period, Mr. Norbe acknowledges that he does so knowingly and voluntarily and waives any claim that to the effect that he was not given the full twenty-one (21) days to consider whether to sign this Agreement or did not use the entire period of time available to consider this Agreement or to consult with an attorney. |
q. |
Seven Day Revocation Period. Following execution of this Agreement, Mr. Norbe shall have seven (7) days to revoke this Agreement. To be effective, the revocation must be in writing and signed by Mr. Norbe and must be delivered to and received by the Company, before 5 p.m. local time of the 7th day. This Agreement shall become effective on the eighth (8th) day following the execution of this Agreement (the “Effective Date”). Any revocation shall be in writing and shall be effective upon timely receipt by the Company by: Corporate Secretary, c/o Legal Department, Biolase, Inc., 27042 Towne Centre Drive, Suite 270, Foothill Ranch, California, 92610. |
4
obligations, actions, causes of action, debts, liabilities, rights, contracts, damages, attorneys’ fees, costs, expenses, losses or claims referred to herein. |
s. |
Successors and Assigns. This Agreement, and all the terms and provisions hereof, shall be binding upon and shall inure to the benefit of the parties and their respective heirs, legal representatives, successors and assigns. |
t. |
Assistance of Counsel. Mr. Norbe acknowledges that he has been advised to consult with counsel of his choosing before entering into this Agreement. The parties specifically represent that they either have consulted to their satisfaction with their attorneys, or have elected on their own accord not to seek legal counsel, prior to executing this Agreement concerning the terms and conditions of this Agreement. |
u. |
Interpretation. Should any portion, word, clause, phrase, sentence or paragraph of this Agreement be declared void or unenforceable, such portion shall be considered independent and severable from the remainder, the validity of which shall remain unaffected. Whenever required by the context, as used in this Agreement the singular number shall include the plural, and the masculine gender shall include the feminine and neuter. |
v. |
Entire Agreement. This Agreement constitutes the entire agreement between the parties who have executed it and supersedes any and all other agreements, understandings, negotiations, or discussions, either oral or in writing, express or implied, between the parties to this Agreement. The parties hereto acknowledge that no representations, inducements, promises, agreements, or warranties, oral or otherwise, have been made by them, or anyone acting on their behalf, which are not embodied in this Agreement, that they have not executed this Agreement in reliance on any such representations, inducements, promise, agreement or warranty, and that no representation, inducement, promise, agreement or warranty not contained in this Agreement, including, but not limited to, any purported supplements, modifications, waivers or terminations of this Agreement shall be valid or binding, unless executed in writing by all of the parties to this Agreement. |
w. |
Governing Law. This Agreement shall be enforced and governed under the laws of the State of California without reference to its choice of law provisions. |
x. |
Knowing and Voluntary Agreement. This Agreement in all respects has been voluntarily and knowingly executed by the parties hereto. |
y. |
Counterparts. This Agreement may be executed in counterparts, and when each party has signed and delivered at least one such counterpart, each counterpart shall be deemed an original, and, when taken together with other signed counterparts, shall constitute one agreement, which shall be binding upon and effective as to all parties. |
z. |
No Waiver. Failure to insist on compliance of any term, covenant or condition contained in this Agreement shall not be deemed a waiver of that term, covenant, or condition, nor shall any waiver or relinquishment of any right or power contained in this Agreement at any one time or more times be deemed a waiver or relinquishment of any right or power at any other time or times. |
5
and under the rules of the Judicial Arbitration and Mediation Service (“JAMS”); provided that nothing in this provision shall prevent the Company from seeking injunctive relief in any Court of competent jurisdiction. |
bb. |
Section 409A. The payments to Mr. Norbe pursuant to this Agreement are intended to be exempt from Section 409A of the Internal Revenue Code of 1986, as amended, to the maximum extent possible, under either the separation pay exemption pursuant to Treasury regulation §1.409A-1(b)(9)(iii) or as short-term deferrals pursuant to Treasury regulation §1.409A-1(b)(4), and for such purposes, each installment paid to Mr. Norbe under this Agreement shall be considered a separate payment. In the event the terms of this Agreement would subject Mr. Norbe to taxes or penalties under Section 409A of the Code (“409A Penalties”), the Company and Mr. Norbe shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible; provided that in no event shall the Company be responsible for any 409A Penalties that arise in connection with any amounts payable under this Agreement. |
IN WITNESS WHEREOF, the undersigned have executed this Separation Agreement and General Release of All Claims on the date(s) set forth hereinafter.
Dated: March 12, 2021 |
By: |
/s/ Todd Norbe |
|
|
|
|
|
|
|
|
|
|
BIOLASE, INC. |
Dated: February 22, 2021 |
By: |
|
|
|
|
|
|
Chairman of the Board |
6
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 3/31/21 | 10-Q | ||
3/12/21 | 8-K | |||
2/22/21 | 8-K | |||
For Period end: | 12/31/20 | |||
8/7/18 | 4, 8-K | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/03/23 Biolase, Inc. S-1/A 6:1M Donnelley … Solutions/FA 12/12/22 Biolase, Inc. S-1/A 7:1.1M Donnelley … Solutions/FA 11/22/22 Biolase, Inc. S-1 3:655K Donnelley … Solutions/FA 3/17/22 Biolase, Inc. 10-K 12/31/21 88:18M Donnelley … Solutions/FA 5/13/21 Biolase, Inc. 10-Q 3/31/21 81:9.4M Donnelley … Solutions/FA |